Abstract:Liying Ma, 1, 2 Yansong Gao, 1 Ge Yang, 1 Lei Zhao, 2 Zijian Zhao, 1 Yujuan Zhao, 1 Yuhang Zhang, 2 Shenhui Li, 2 Shengyu Li 1 1 Institute of Agro-food Technology, Jilin Academy of Agricultural Sciences (Northeast Agricultural Research Center of China), Changchun, 130033, People's Republic of China; 2 School of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun, 130117, People's Republic of China Correspondence: Shengyu Li, Institute of Agro-Food Technology, Jilin Academy of Agricultural Sciences (Northeast Agricultural Research Center of China), No. 1363 Sheng-Tai Street, Changchun, Jilin Province, 130033, People's Republic of China, Tel +86 431 87063289, Fax +86 431 87063075, Email Aim: Natural medicines possess significant research and application value in the field of atherosclerosis (AS) treatment. The study was performed to investigate the impacts of a natural drug component, notoginsenoside R1, on the development of atherosclerosis (AS) and the potential mechanisms. Methods: Rats induced with AS by a high-fat-diet and vitamin D3 were treated with notoginsenoside R1 for six weeks. The ameliorative effect of NR1 on AS rats was assessed by detecting pathological changes in the abdominal aorta, biochemical indices in serum and protein expression in the abdominal aorta, as well as by analysing the gut microbiota. Results: The NR1 group exhibited a noticeable reduction in plaque pathology. Notoginsenoside R1 can significantly improve serum lipid profiles, encompassing TG, TC, LDL, ox-LDL, and HDL. Simultaneously, IL-6, IL-33, TNF-α, and IL-1β levels are decreased by notoginsenoside R1 in lowering inflammatory elements. Notoginsenoside R1 can suppress the secretion of VCAM-1 and ICAM-1, as well as enhance the levels of plasma NO and eNOS. Furthermore, notoginsenoside R1 inhibits the NLRP3/Cleaved Caspase-1/IL-1β inflammatory pathway and reduces the expression of the JNK2/P38 MAPK/VEGF endothelial damage pathway. Fecal analysis showed that notoginsenoside R1 remodeled the gut microbiota of AS rats by decreasing the count of pathogenic bacteria (such as Firmicutes and Proteobacteria ) and increasing the quantity of probiotic bacteria (such as Bacteroidetes ). Conclusion: Notoginsenoside R1, due to its unique anti-inflammatory properties, may potentially prevent the progression of atherosclerosis. This mechanism helps protect the vascular endothelium from damage, while also regulating the imbalance of intestinal microbiota, thereby maintaining the overall health of the body. Keywords: notoginsenoside R1, inflammation, endothelial damage, gut microbiota Graphical In China and worldwide, cardiovascular diseases (CVDs) are primary cause of fatalities, impairments, and a significant health burden. Atherosclerosis (AS), a chronic condition characterized by the buildup of lipids and fibrous substances in large arteries, plays a significant role in the onset and progression of CVDs. 1 Thus, preventing the development and advancement of AS could potentially reduce the mortality rate due to CVDs. Chronic inflammation theory, lipid infiltration theory, and endothelial injury theory have occupied important positions 2 in the study of the pathophysiological mechanisms of AS. It is subject to numerous factors, incorporating pathological mechanisms like inflammation, oxidative stress, apoptosis, and lipid buildup. 3 The features of AS primarily involve the participation of immunity and inflammation. Prolonged development of inflammation in the arterial intima leads to pathological changes in the aorta and triggers endothelial damage. 4 This ultimately results in the formation of plaques and increases plaque instability. 5 The development of AS is thought to coincide with flow-mediated inflammatory alterations in endothelial cells (ECs). Possible mechanisms of inflammation include cellular senescence, NLRP3 inflammasome activation, oxidative stress, increased intestinal permeability, and lifestyle and dietary effects on microbial composition. 6,7 Meanwhile, endothelial dysfunction also promotes rupture of atherosclerotic plaques. 8 Furthermore, growing research suggests that changes in the in the composition and function of intestinal microbiota can lead to disruptions in lipid metabolism and intestinal inflammation, which ultimately contribute to the initiation and advancement of AS. 9 Disturbances in intestinal microbiota and over colonization by harmful bacteria can damage the intestinal mucosa, disrupting its integrity and leading to greater permeability, which triggers an a -Abstract Truncated-

Ginsenoside F1 Ameliorates Endothelial Cell Inflammatory Injury and Prevents Atherosclerosis in Mice through A20-Mediated Suppression of NF-kB Signaling.

Ginsenoside Rg1-Notoginsenoside R1-Protocatechuic Aldehyde Reduces Atherosclerosis and Attenuates Low-Shear Stress-Induced Vascular Endothelial Cell Dysfunction

Ginsenoside Rg3 Alleviates ox-LDL Induced Endothelial Dysfunction and Prevents Atherosclerosis in ApoE−/− Mice by Regulating PPARγ/FAK Signaling Pathway

Notoginsenoside R1 alleviates oxidized low-density lipoprotein-induced apoptosis, inflammatory response, and oxidative stress in HUVECS through modulation of XIST/miR-221-3p/TRAF6 axis

Endothelial Foxp1 Suppresses Atherosclerosis Via Modulation of Nlrp3 Inflammasome Activation.

Possible Role of Fibroblast Growth Factor 21 on Atherosclerosis Via Amelioration of Endoplasmic Reticulum Stress-Mediated Apoptosis in Apoe−/− Mice

Notoginsenoside R1 Attenuates Atherosclerotic Lesions in ApoE Deficient Mouse Model.

Attenuation of TNF-α-Induced Inflammatory Injury in Endothelial Cells by Ginsenoside Rb1 via Inhibiting NF-κB, JNK and p38 Signaling Pathways.

Ginsenoside-Rd, A Purified Component from Panax Notoginseng Saponins, Prevents Atherosclerosis in Apoe Knockout Mice

Notoginsenoside R1 upregulates miR-221-3p expression to alleviate ox-LDL-induced apoptosis, inflammation, and oxidative stress by inhibiting the TLR4/NF-κB pathway in HUVECs

Notoginsenoside R1 Ameliorate High-Fat-Diet and Vitamin D3-Induced Atherosclerosis via Alleviating Inflammatory Response, Inhibiting Endothelial Dysfunction, and Regulating Gut Microbiota

Inhibition of Vascular Neointima Hyperplasia by FGF21 Associated with FGFR1/Syk/NLRP3 Inflammasome Pathway in Diabetic Mice

Anhuienoside C Ameliorates Atherosclerosis in Rats Via Regulation of the NFκB/eNOS/NO Signaling Pathway

Experimental Studies on Anti-atherosclerotic Effects and Mechanisms of Ginsenoside Rh2

Ginsenoside Rc Ameliorated Atherosclerosis Via Regulating Gut Microbiota and Fecal Metabolites

Ginsenoside Rg1-Notoginsenoside R1-Protocatechuic aldehyde attenuates low shear stress-induced vascular endothelial cell dysfunction

Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model

Geniposide Combined With Notoginsenoside R1 Attenuates Inflammation and Apoptosis in Atherosclerosis via the AMPK/mTOR/Nrf2 Signaling Pathway

Therapeutic Effects of Fibroblast Growth Factor‑21 Against Atherosclerosis Via the NF‑κB Pathway.

Gastrodin ameliorates atherosclerosis by inhibiting foam cells formation and inflammation through down-regulating NF-κB pathway

Anti-Atherosclerosis Effect of Angong Niuhuang Pill via Regulating Th17/Treg Immune Balance and Inhibiting Chronic Inflammatory on ApoE -/- Mice Model of Early and Mid-Term Atherosclerosis.